Akoya Biosciences Company Insiders
AKYA Stock | USD 2.11 0.01 0.47% |
Akoya Biosciences' insiders are aggressively selling. The analysis of insiders' sentiment of trading Akoya Biosciences stock suggests that vertually all insiders are panicking at this time. Akoya Biosciences employs about 330 people. The company is managed by 15 executives with a total tenure of roughly 770 years, averaging almost 51.0 years of service per executive, having 22.0 employees per reported executive.
Akoya Biosciences' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-06-11 | Brian Mckelligon | Disposed 7500 @ 2.08 | View | ||
2024-06-06 | Brian Mckelligon | Disposed 7500 @ 2.01 | View | ||
2024-03-20 | Brian Mckelligon | Disposed 7500 @ 4.97 | View | ||
2024-03-13 | Brian Mckelligon | Disposed 7500 @ 4.94 | View | ||
2023-12-19 | Brian Mckelligon | Disposed 7500 @ 4.48 | View |
Monitoring Akoya Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Akoya |
Akoya Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.1809) % which means that it has lost $0.1809 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.282) %, meaning that it created substantial loss on money invested by shareholders. Akoya Biosciences' management efficiency ratios could be used to measure how well Akoya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.42. At present, Akoya Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 59.4 M, whereas Total Assets are forecasted to decline to about 157.2 M.As of November 22, 2024, Common Stock Shares Outstanding is expected to decline to about 42.6 M. The current year's Net Loss is expected to grow to about (60.4 M)
Akoya Biosciences Workforce Comparison
Akoya Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 50,092. Akoya Biosciences maintains roughly 330 in number of employees contributing less than 1% to equities under Health Care industry.
Akoya Biosciences Profit Margins
The company has Profit Margin (PM) of (0.65) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.47) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.47.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.66 | 0.5827 |
|
|
Akoya Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akoya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akoya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Akoya Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 0.2 | 1 | 5 | 40,000 | 240,000 |
2024-06-01 | 1.6 | 8 | 5 | 315,000 | 44,272 |
2024-03-01 | 0.9286 | 13 | 14 | 1,067,092 | 436,120 |
2023-12-01 | 0.8333 | 5 | 6 | 82,500 | 45,000 |
2023-06-01 | 8.0 | 16 | 2 | 2,802,642 | 10,000 |
2023-03-01 | 2.0 | 16 | 8 | 947,750 | 55,327 |
2022-12-01 | 0.2857 | 4 | 14 | 279,613 | 401,147 |
2022-09-01 | 0.2 | 1 | 5 | 5,000 | 42,296 |
2022-06-01 | 4.3333 | 13 | 3 | 561,146 | 10,000 |
2022-03-01 | 5.0 | 5 | 1 | 372,500 | 0.00 |
2021-12-01 | 2.5 | 5 | 2 | 68,573 | 25,100 |
2021-09-01 | 1.0 | 1 | 1 | 38,993 | 0.00 |
2021-06-01 | 0.3158 | 6 | 19 | 119,862 | 1,145,858 |
Akoya Biosciences Notable Stakeholders
An Akoya Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Akoya Biosciences often face trade-offs trying to please all of them. Akoya Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Akoya Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Brian McKelligon | CEO President | Profile | |
Pascal Bamford | Research President | Profile | |
John Ek | Principal CFO | Profile | |
Clifford Hoyt | VP Affairs | Profile | |
Marilee MBA | Chief Officer | Profile | |
Jennifer Kamocsay | General Counsel | Profile | |
Nikolay Samusik | CoFounder | Profile | |
Priyam Shah | Senior Strategy | Profile | |
JD CFA | Secretary | Profile | |
Niro Ramachandran | Chief Officer | Profile | |
Yury Goltsev | CoFounder | Profile | |
Joseph Driscoll | Chief Officer | Profile | |
Garry Nolan | Independent CoFounder | Profile | |
Paul Grass | Senior Sales | Profile | |
Frederic Pla | Chief Officer | Profile |
About Akoya Biosciences Management Performance
The success or failure of an entity such as Akoya Biosciences often depends on how effective the management is. Akoya Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Akoya management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Akoya management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.44) | (0.46) | |
Return On Capital Employed | (0.40) | (0.42) | |
Return On Assets | (0.35) | (0.37) | |
Return On Equity | (1.18) | (1.24) |
Please note, the presentation of Akoya Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akoya Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Akoya Biosciences' management manipulating its earnings.
Akoya Biosciences Workforce Analysis
Traditionally, organizations such as Akoya Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Akoya Biosciences within its industry.Akoya Biosciences Manpower Efficiency
Return on Akoya Biosciences Manpower
Revenue Per Employee | 292.8K | |
Revenue Per Executive | 6.4M | |
Net Loss Per Employee | 191.9K | |
Net Loss Per Executive | 4.2M | |
Working Capital Per Employee | 262K | |
Working Capital Per Executive | 5.8M |
Complementary Tools for Akoya Stock analysis
When running Akoya Biosciences' price analysis, check to measure Akoya Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akoya Biosciences is operating at the current time. Most of Akoya Biosciences' value examination focuses on studying past and present price action to predict the probability of Akoya Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akoya Biosciences' price. Additionally, you may evaluate how the addition of Akoya Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |